Radiopharmaceuticals Market by Indications (Cardiovascular, Oncology, Neurological, Thyroid, Gastrointestinal), Therapeutics (Systemic Oncology Using Iodine, Yttrium, Samarium, Strontium, Rhenium, Lutetium, Erbium; Cardiology, Neurology), Technologies (SPECT – Technetium, Thallium, Gallium, Iodine, Rhenium, Yttrium; PET – Fludeoxyglucose, Rubidium, Carbon-11 Choline, Nitrogen-13 Ammonia), Generators (Mo-99/Tc-99M, Sr-82/Rb-82, Ge-68/Ga-68, Sr-90/Y-90, and W-188/Re-188 Generators), and End Users (Diagnostic Centers, Hospitals and Medical Centers) and Forecast 2017-2021

Radiopharmaceuticals Market by Indications (Cardiovascular, Oncology, Neurological, Thyroid, Gastrointestinal), Therapeutics (Systemic Oncology Using Iodine, Yttrium, Samarium, Strontium, Rhenium, Lutetium, Erbium; Cardiology, Neurology), Technologies (SPECT – Technetium, Thallium, Gallium, Iodine, Rhenium, Yttrium; PET – Fludeoxyglucose, Rubidium, Carbon-11 Choline, Nitrogen-13 Ammonia), Generators (Mo-99/Tc-99M, Sr-82/Rb-82, Ge-68/Ga-68, Sr-90/Y-90, and W-188/Re-188 Generators), and End Users (Diagnostic Centers, Hospitals and Medical Centers) and Forecast 2017-2021

Medicinal radiocompounds or radiopharmaceuticals are a group of pharmaceutical drugs which have radioactivity and they can be used as diagnostic and therapeutic agents. Radiopharmaceuticals are used in the field of nuclear medicine as radioactive tracers in medical imaging and functional studies of the brain, myocardium, thyroid, lungs, liver, gallbladder, kidneys, skeleton, blood and tumors, and in therapy for many diseases. Radiopharmaceuticals imply the usage of radiation for non-invasive treatment and diagnosis of various diseases. Utilization of these molecules for medical purposes in PET and SPECT imaging has changed the entire algorithm of disease diagnosis.

The global radiopharmaceuticals market report estimates the market size (Revenue US$ million – 2014 to 2021) for key market segments based on the indications (cardiovascular, oncology, neurological, thyroid, gastrointestinal, etc.), therapeutics (systemic oncology using Iodine, Yttrium, Samarium, Strontium, Rhenium, Lutetium, Erbium; cardiology, neurology, etc.), technologies (SPECT – Technetium, Thallium, Gallium, Iodine, Rhenium, Yttrium; PET – Fludeoxyglucose, Rubidium, Carbon-11 Choline, Nitrogen-13 Ammonia, etc.), generators (Mo-99/Tc-99m, Sr-82/Rb-82, Ge-68/Ga-68, Sr-90/Y-90, and W-188/Re-188 generators), end users (diagnostic centers, hospitals and medical centers), and forecasts growth trends (CAGR% – 2017 to 2021).

The global radiopharmaceuticals market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global radiopharmaceuticals market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.

Major players operating in the global radiopharmaceuticals market and included in this report are Cardinal Health Inc., Covidien Plc, GE Healthcare, IBA Group, Lantheus Medical Imaging, Monrol Nuclear Products, Inc., Nordion, Inc., NTP Radioisotopes Ltd., Polatom, Positron Corporation, and Siemens Healthcare.

Category:
  1. Introduction
  2. Executive Summary
    • Market Size Estimation (Revenue US$ Million, 2014-2021)
    • Forecast Estimation (Revenue US$ Million and CAGR%, 2017-2021)
  3. Research Methodology
  4. Market Landscape
    • Market Dynamics
      • Drivers
      • Barriers
      • Opportunities
    • Market Share Analysis
      • Companies
      • Drugs
    • Market Trends Analysis
      • Key success factors
      • Market Growth Rate
    • Market Attractiveness Analysis
    • Market Profitability Analysis
      • Buyer power
      • Supplier power
      • Barriers to entry
      • Threat of substitute products
      • Rivalry among firms in the industry
    • Distribution Channels
  5. Market Segmentation [refer Market Segments and Companies Tab]
    • Drug Class or Drug (Brand) Type
    • Drug or Disorder Test
    • Indication Type
    • Drug Treatment
    • Mechanism of Action
    • Therapeutic Area or Nature of Application
    • End User Groups
  6. Geography (Region, Country)
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Rest of the World (Middle East & Africa)
  7. Regulatory Overview 
    • IND, NDA filed, FDA, EMEA Approvals
  8. Pipeline Analysis(Phase 1, 2 and 3 Drugs)
    • Phase 3 Drugs Forecast Estimation (Approval to 2025)
    • Phase 1 and 2 Drugs – Qualitative Analysis
  9. Company Profiles [refer Market Segments and Companies Tab]
    • Company Overview
    • Financial Snapshot (FY 2014-2016)
    • Product Portfolio
    • Business Strategies
    • Recent Developments
  10. Recommendations
  11. References

Radiopharmaceuticals Market

1. Indication
1.1. Cardiovascular
1.2. Oncology
1.3. Others (Neurological, Thyroid, Gastrointestinal)

2. Therapy
2.1. Systemic Oncology
2.1.1. Iodine (I-131)
2.1.2. Yttrium (90Y)
2.1.3. Samarium (Sm-153)
2.1.4. Strontium (89Sr)
2.1.5. Rhenium (186Re)
2.1.6. Lutetium (Lu-177)
2.1.7. Erbium (169Er)
2.1.8. Others
2.2. Others (Cardiology, Neurology)

3. Technology
3.1. Single-Photon Emission Computed Tomography (SPECT)
3.1.1. Technetium (Tc-99m)
3.1.2. Thallium (TI-201)
3.1.3. Gallium (Ga-67)
3.1.4. Iodine (I-123)
3.1.5. Rhenium (Re-186)
3.1.6. Yttrium (Y-90)
3.1.7. Others
3.2. Positron Emission Tomography (PET)
3.2.1. Fludeoxyglucose (18F-FDG)
3.2.2. Rubidium (Rb-82)
3.2.3. Others (Carbon-11 Choline, Nitrogen-13 Ammonia)

4. Generator Type
4.1. Mo-99/Tc-99m Generator
4.2. Sr-82/Rb-82 Generator
4.3. Ge-68/Ga-68 Generator
4.4. Sr-90/Y-90 Generator
4.5. W-188/Re-188 Generator

5. End User
5.1. Diagnostic Centers
5.2. Hospitals & Medical Centers

6. Company Profiles
6.1. Cardinal Health Inc.
6.2. Covidien Plc
6.3. GE Healthcare
6.4. IBA Group
6.5. Lantheus Medical Imaging
6.6. Monrol Nuclear Products, Inc.
6.7. Nordion, Inc.
6.8. NTP Radioisotopes Ltd.
6.9. Polatom
6.10. Positron Corporation
6.11. Siemens Healthcare

Request market specific full ToC and sample pages for this report

Full Name*

Email*

Phone Number* [Please add country code]

Subject*

Message*